Home

The Domino Effect

This week, in what was a somewhat nostalgic moment for me, Cryoport (CYRX)'s earnings hit the newswire. For long time readers of TW, you...

Trading Alert, August 5th, 2022

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

Trading Alert, August 2nd, 2022

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

Micros Rallied in July, Can It Continue?

Just when it's hottest in NY, and all the bankers have taken off for the Hamptons, we get to earnings season for the micro-caps...

Spectra7 Announces $8.0 Million Convertible Debenture Financing; Closing of First Tranche

TW's Take: this is great news for the company as it takes funding risk off the table, allowing them to focus on their rapidly...

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to...

TW's Take: positive progress for this totally beaten down stock. When will the market wake up to this opportunity? MBIO is a partner company...

Dog Days of Summer

Markets had a solid week but Friday was a classic example of what can happen during the slow summer months. Liquidity dries up and,...

Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast Cancer Vaccine Technology

TW's Take: Anixa continues to move this program forward. Expect compelling data from the ongoing phase 1 trial sometime late in 2022. SAN JOSE, Calif., July...

Trading Alert, July 19th, 2022

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

Taking the Long View on TFF

This week my group had a Zoom call with TFF Pharma (TFFP). Over the past year TFF has become a very polarizing stock. There...

TFF Pharmaceuticals Expands R&D Operations with New Austin Facility

TW's Take: this quote, "as many of our partnered programs move to clinical evaluation", is what the investment community is looking for. When TFF...

Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for...

TW's Take: this trial has the potential to change the perception of Lantern as success here would immediately revalue this company. Results expected sometime...

Catalysts Aplenty, a 2nd Half Preview

It's tough to read too much into a small sample size but the first week of July's stock performance has me thinking that my...

Texas Court Grants ParkerVision Motion to Add Willfulness to Intel Complaint

TW's Take: good progress for Parker as the court case against Intel get closer and closer... JACKSONVILLE, FL / ACCESSWIRE / July 6, 2022 /...

enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering...

TW's Take: important step towards full coverage of the Venovalve. NVNO trades below cash, is funded through approval, and the product will likely be...

Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at...

DUBLIN, Ireland, and Boston MA, July 7, 2022,  Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments...

June in Review

Okay, so I lied. I said that I wouldn't have a newsletter this week but couldn't help myself and here we are with a...

This Week’s Newsletter

In a welcome, and overdue respite, markets rallied this past week. As we have been suggesting would be the case, the relief rally was...

European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB

TW's Take: positive news for AMYT as they now have a 4th product on the market. This is a sleeper stock with solid growth...

Spectra7 Expands Availability of Active Copper Cables with new Design-in with ACES to Deliver...

TW's Take: SPVNF is well positioned in several growing markets and, as supply chain issues alleviate, sales should begin to accelerate rapidly. SAN JOSE, CA...

Become a TW Research Member

All our articles are free for everyone to enjoy, however you must register as a user. Please take the time to sign up, it’s free and we do not share your information with anyone.

For those interested in receiving alerts when we buy or sell stocks for our managed accounts, you should consider becoming a premium subscriber. A premium subscription costs $500 per year and subscribers get emails about every transaction taken in our portfolios, including names that have yet to be added to the Tailwinds site.

SIGN ME UP

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.